// App-Quantinova.ai

1183 : Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Researchers

Presenter

  • Paolo F Caimi

Principal Investigators

  • Weiyun Z. Ai

  • Juan Pablo Alderuccio

  • Kirit M. Ardeshna

  • Mehdi Hamadani

  • Brian T. Hess

  • Brad S. Kahl

  • John A. Radford

  • Melhem Solh

  • Anastasios Stathis

  • Pier Luigi Zinzani

  • Jay Feingold

  • David Ungar

  • Yajuan Qin

  • Shui He

  • Carmelo Carlo-Stella

Medical Centers

  • University Hospitals Cleveland Medical Center / Case Western Reserve University School of Medicine, Cleveland, OH

  • Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Orange, CA

  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

  • Division of Hematology and Medical Oncology, Department of Medicine,Medical University of South Carolina,Charleston,États-unis

  • Department of Medicine, Oncology Division, Washington University, St. Louis, MO

  • The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA

  • Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • ADC Therapeutics America, Inc, Murray Hill

  • Clinical Development, ADC Therapeutics, Murray Hill, NJ

  • Department of Oncology and Hematology,Humanitas Clinical and Research Center - IRCCS and Humanitas University,Rozzano, Milano,Italy

Locations

  • United States

  • United Kingdom

  • Switzerland

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT03589469

Sponsors

  • ADC Therapeutics

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved